Analysts’ Viewpoint
The emergence of SARS-CoV-2, which triggered the COVID-19 pandemic with overall 662,735,182 cases to date, is widely regarded as the greatest medical emergency of the twentieth century. COVID-19 has highlighted health disparities with 6,706,305 death cases, both within and between countries, and its impact on global society would be felt for a long time. Nonetheless, significant investment in life sciences in the last few decades has facilitated a rapid scientific response through advances in viral characterization, testing, and sequencing.
The coronavirus treatment, and vaccination market witnessed significant increase in demand due to the desire of governments and people to safeguard themselves and their loved ones from the virus. Technology advancements have facilitated the rapid development of COVID medications therapies and vaccinations. In a relatively short amount of time, emerging technologies, such as CRISPR and mRNA, have made it possible to develop new medicines. Pharmaceutical corporations, biotech companies, academic institutions, and governmental entities have worked closely together to create COVID-19 treatments. New therapies and vaccines have been developed and distributed more rapidly because of this collaboration.
Demand for COVID-19 treatments may be influenced by the ongoing coronavirus mutational alterations that are currently affecting parts of the world, including China. The need for COVID-19 vaccines and therapies has boosted spending on research and development as well as the manufacturing and distribution of medications. Governments across the globe have taken steps to guarantee that people have access to COVID-19 treatments, which has further fueled the COVID-19 therapeutics industry.
Monoclonal antibodies such as bamlanivimab, casirivimab and imdevimab, developed by companies such as Eli Lilly, Regeneron, and AstraZeneca, have been authorized for emergency use by the FDA and EMA for the treatment of mild to moderate COVID-19 in high-risk patients.
Furthermore, according to the industry analysis of COVID-19 therapeutics, increase in the number of clinical trials for COVID-19 therapeutics, including phase III clinical trials for vaccines and phase II/III clinical trials for therapeutics, such as monoclonal antibodies and antiviral drugs, are likely to be responsible for COVID-19 therapeutics market growth in the near future.
Demand for drugs that can effectively treat new strains of the virus is likely to be significantly high, as these new variants may be less susceptible to existing therapeutics. This is projected to boost the COVID-19 therapeutics market size, as pharmaceutical companies race to develop new drugs and treatments to address these new variants.
Even after the pandemic is under control, there would still be a need for treatments and therapies to help those who have been affected by the virus, including those with long-term effects. This is anticipated to continue to drive COVID-19 therapeutics market demand. Additionally, emergence of new variants of the virus and the possibility of future outbreaks are anticipated to prompt governments and private organizations to be better prepared for future pandemics.
Government and private organizations have been investing heavily in the development of new therapeutics for COVID-19 treatment. This is due in part to the urgency of the pandemic and the need for effective treatments and vaccines. These investments have helped accelerate the development and availability of new therapeutics and have driven the COVID-19 therapeutics market value.
Governments and private organizations have also formed public-private partnerships to accelerate the development of COVID-19 therapeutics. For instance, in April 2020, Gilead Sciences received an investment of US$ 483 Mn from the U.S. government to develop and produce remdesivir, an antiviral drug that was granted Emergency Use Authorization (EUA) by the FDA for the treatment of COVID-19. Furthermore, the U.S. government invested US$ 1.95 Bn in Moderna for the creation and production of their COVID-19 mRNA vaccine.
Governments have also authorized Emergency Use Authorization (EUA) for some drugs and vaccines as a measure to speed up their availability to the public. Therefore, these investments have played a key role in the rapid development and distribution of new treatments and vaccines for COVID-19. This has helped to mitigate the impact of the pandemic on global economies and healthcare systems. Moreover, this is expected to continue to drive COVID-19 therapeutics market developments in the future.
According to the global COVID-19 therapeutics market segmentation, the antiviral drug class segment is expected to account for a considerable COVID-19 therapeutics market share during the forecast period.
Antiviral drugs are used in the treatment of COVID-19 because they can target and inhibit the replication of the virus that causes the disease, SARS-CoV-2. Antiviral drugs can help reduce the severity of symptoms and the duration of illness by slowing or stopping the replication of the virus. These drugs can be used as a monotherapy or in combination with other medications and therapies to improve treatment outcomes.
The approval and distribution of antiviral drugs for COVID-19 have been faster than that of vaccines and monoclonal antibodies. This made them one of the first lines of defense in treating the virus. Furthermore, the WHO and other health organizations have recommended the use of antiviral drugs in the treatment of COVID-19. These factors are driving market growth of COVID-19 therapeutics.
According to the latest COVID-19 therapeutics market trends, the parenteral route of administration is highly preferred for the treatment of COVID-19, as it allows for rapid medication delivery to the patient. The medication is administered directly into the bloodstream, bypassing the digestive system, which can help to ensure that the patient receives the full dose of medication on time.
Furthermore, patients with severe cases of COVID-19 may require high doses of medication to be administered rapidly, and the parenteral route of administration is ideal, as it does not depend on the patient's ability to swallow or absorb the medication. It also allows for the delivery of the drugs in a controlled and accurate manner, which is important for effective treatment and avoiding potential side-effects.
According to the WHO, North America has been one of the regions most affected by the COVID-19 pandemic, as the US has high numbers of confirmed cases of 100,304,472 and deaths of 1,088,854. This has led to an increased demand for medication and other therapeutics to treat the disease. Furthermore, regional analysis of research insights of the COVID-19 therapeutics market reveal that this region has a well-developed healthcare infrastructure, with a high concentration of hospitals, clinics, and pharmacies. This has allowed for the efficient distribution and administration of medication and other therapeutics to patients in need.
Europe has also been affected by the COVID-19 pandemic, as it also has a large population and high expenditure on healthcare, which has enabled the region to invest in research and development of new therapeutics, as well as in the distribution and administration of existing treatments.
The Asia Pacific market is expected to grow at a rapid pace in the next few years due to the rising incidence of COVID-19 cases and the increasing government support for the treatment and prevention of the disease.
The global market is fragmented, with the presence of a large number of players according to the COVID-19 therapeutics market forecast. Key players operating in the industry are F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Eli Lilly and Company, Pfizer Inc., Merck & Co., Inc. GSK plc. Celltrion Healthcare Co., Ltd., Sorrento Therapeutics, Inc., and AstraZeneca.
|
Attribute |
Detail |
|
Size in 2021 |
US$ 30.7 Bn |
|
Forecast Value in 2031 |
More than US$ 16.2 Bn |
|
CAGR - 2022–2031 |
-8.3 % |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
.Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
The global market was valued at US$ 30.7 Bn in 2021.
It is projected to reach more than US$ 16.2 Bn by 2031.
It is anticipated to be - 8.3% from 2022 to 2031.
The parenteral segment held more than 80.0% share in 2021.
North America is expected to account for largest share from 2022 to 2031.
F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Eli Lilly and Company, Pfizer Inc., Merck & Co., Inc. GSK plc. Celltrion Healthcare Co., Ltd., Sorrento Therapeutics, Inc., and AstraZeneca.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global COVID-19 Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global COVID-19 Therapeutics Market Analysis and Forecasts, 2017 - 2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Pipeline Analysis
5.3. Regulatory Scenario by Region/globally
5.4. COVID-19 Impact Analysis
6. Global COVID-19 Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017 - 2031
6.3.1. Corticosteroids
6.3.2. Anti-viral
6.3.3. Monoclonal Antibodies
6.3.4. Kinase Inhibitors
6.3.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
6.4. Market Attractiveness, by Drug Class
7. Global COVID-19 Therapeutics Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017 - 2031
7.3.1. Oral
7.3.2. Parenteral
7.4. Market Attractiveness, by Route of Administration
8. Global COVID-19 Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel
9. Global COVID-19 Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Country/Region
10. North America COVID-19 Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017 - 2031
10.2.1. Corticosteroids
10.2.2. Anti-viral
10.2.3. Monoclonal Antibodies
10.2.4. Kinase Inhibitors
10.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
10.3. Market Value Forecast, by Route of Administration, 2017 - 2031
10.3.1. Oral
10.3.2. Parenteral
10.4. Market Value Forecast, by Distribution Channel, 2017 - 2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017 - 2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe COVID-19 Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017 - 2031
11.2.1. Corticosteroids
11.2.2. Anti-viral
11.2.3. Monoclonal Antibodies
11.2.4. Kinase Inhibitors
11.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
11.3. Market Value Forecast, by Route of Administration, 2017 - 2031
11.3.1. Oral
11.3.2. Parenteral
11.4. Market Value Forecast, by Distribution Channel, 2017 - 2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017 - 2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific COVID-19 Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017 - 2031
12.2.1. Corticosteroids
12.2.2. Anti-viral
12.2.3. Monoclonal Antibodies
12.2.4. Kinase Inhibitors
12.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
12.3. Market Value Forecast, by Route of Administration, 2017 - 2031
12.3.1. Oral
12.3.2. Parenteral
12.4. Market Value Forecast, by Distribution Channel, 2017 - 2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017 - 2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America COVID-19 Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017 - 2031
13.2.1. Corticosteroids
13.2.2. Anti-viral
13.2.3. Monoclonal Antibodies
13.2.4. Kinase Inhibitors
13.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
13.3. Market Value Forecast, by Route of Administration, 2017 - 2031
13.3.1. Oral
13.3.2. Parenteral
13.4. Market Value Forecast, by Distribution Channel, 2017 - 2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017 - 2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa COVID-19 Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017 - 2031
14.2.1. Corticosteroids
14.2.2. Anti-viral
14.2.3. Monoclonal Antibodies
14.2.4. Kinase Inhibitors
14.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
14.3. Market Value Forecast, by Route of Administration, 2017 - 2031
14.3.1. Oral
14.3.2. Parenteral
14.4. Market Value Forecast, by Distribution Channel, 2017 - 2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017 - 2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & South Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2021)
15.3. Company Profiles
15.3.1. F. Hoffmann-La Roche Ltd
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Gilead Sciences, Inc.
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. Eli Lilly and Company
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. Pfizer Inc.
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. Merck & Co., Inc.
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. GSK plc.
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Recent Developments
15.3.7. Celltrion Healthcare Co., Ltd.
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Sorrento Therapeutics, Inc.
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. AstraZeneca
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments
List of Tables
Table 01: Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 02: Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 03: Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
Table 04: Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 07: North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 08: North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
Table 09: Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 10: Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 11: Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 12: Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
Table 13: Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 15: Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 16: Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
Table 17: Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 19: Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 20: Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 23: Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 24: Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
List of Figures
Figure 01: Global COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: COVID-19 Therapeutics Market Value Share, by Drug Class, 2021
Figure 03: COVID-19 Therapeutics Market Value Share, by Route of Administration, 2021
Figure 04: COVID-19 Therapeutics Market Value Share, by Distribution Channel, 2021
Figure 05: COVID-19 Therapeutics Market Value Share, by Region, 2021
Figure 06: Global COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 07: Global COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 08: Global COVID-19 Therapeutics Market Value (US$ Mn), by Corticosteroids, 2017‒2031
Figure 09: Global COVID-19 Therapeutics Market Value (US$ Mn), by Anti-viral, 2017‒2031
Figure 10: Global COVID-19 Therapeutics Market Value (US$ Mn), by Monoclonal Antibodies, 2017‒2031
Figure 11: Global COVID-19 Therapeutics Market Value (US$ Mn), by Kinase Inhibitors, 2017‒2031
Figure 12: Global COVID-19 Therapeutics Market Value (US$ Mn), by Others (Anti-inflammatory Drugs, Convalescent Plasma, Others) 2017‒2031
Figure 13: Global COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 14: Global COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 15: Global COVID-19 Therapeutics Market Value (US$ Mn), by Parenteral, 2017‒2031
Figure 16: Global COVID-19 Therapeutics Market Value (US$ Mn), by Oral, 2017‒2031
Figure 17: Global COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel 2021 and 2031
Figure 18: Global COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel 2022–2031
Figure 19: Global COVID-19 Therapeutics Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031
Figure 20: Global COVID-19 Therapeutics Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031
Figure 21: Global COVID-19 Therapeutics Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031
Figure 22: Global COVID-19 Therapeutics Market Value Share Analysis, by Region, 2021 and 2031
Figure 23: Global COVID-19 Therapeutics Market Attractiveness Analysis, by Region, 2022–2031
Figure 24: North America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 25: North America COVID-19 Therapeutics Market Value Share Analysis, by Country, 2021 and 2031
Figure 26: North America COVID-19 Therapeutics Market Attractiveness Analysis, by Country, 2022–2031
Figure 27: North America COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 28: North America COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class 2022–2031
Figure 29: North America COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 30: North America COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration 2022–2031
Figure 31: North America COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 32: North America COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 33: Europe COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 34: Europe COVID-19 Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 35: Europe COVID-19 Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 36: Europe COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 37: Europe COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 38: Europe COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 39: Europe COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 40: Europe COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 41: Europe COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 42: Asia Pacific COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 43: Asia Pacific COVID-19 Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 44: Asia Pacific COVID-19 Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 45: Asia Pacific COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 46: Asia Pacific COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 47: Asia Pacific COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 48: Asia Pacific COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 49: Asia Pacific COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 50: Asia Pacific COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 51: Latin America COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 52: Latin America COVID-19 Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 53: Latin America COVID-19 Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 54: Latin America COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 55: Latin America COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 56: Latin America COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 57: Latin America COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 58: Latin America COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 59: Latin America COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 60: Middle East & Africa COVID-19 Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 61: Middle East & Africa COVID-19 Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 62: Middle East & Africa COVID-19 Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 63: Middle East & Africa COVID-19 Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 64: Middle East & Africa COVID-19 Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 65: Middle East & Africa COVID-19 Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 66: Middle East & Africa COVID-19 Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 67: Middle East & Africa COVID-19 Therapeutics Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 68: Middle East & Africa COVID-19 Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 69: Company Share Analysis
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
COVID-19 Therapeutics Market
